Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 58.05% |
| 2 | Technology | 7.69% |
| 3 | Financials | 6.83% |
| 4 | Healthcare | 6.42% |
| 5 | Industrials | 4.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BMTC
3451
DELISTED
Bryn Mawr Bank Corp
BMTC
| $2.86M | ﹤0.01% |
62,163
+35,845
| +136% | +$1.45M |
|
|
ACAHU
3452
DELISTED
Atlantic Coastal Acquisition Corp. Unit
ACAHU
| $2.86M | ﹤0.01% |
288,755
-185,739
| -39% | -$1.85M |
|
3453
Douglas Dynamics
PLOW
$965M
| $2.85M | ﹤0.01% |
78,560
-6,807
| -8% | -$262K |
|
3454
LCNB Corp
LCNB
$277M
| $2.85M | ﹤0.01% |
161,637
-92,650
| -36% | -$1.58M |
|
3455
Corvus Pharmaceuticals
CRVS
$1.19B
| $2.85M | ﹤0.01% |
588,272
+456,837
| +348% | +$1.35M |
|
|
EFOR
3456
Everforth Inc
EFOR
$1.31B
| $2.85M | ﹤0.01% |
25,156
-37,415
| -60% | -$3.94M |
|
|
BRFS
3457
DELISTED
BRF SA
BRFS
| $2.84M | ﹤0.01% |
566,100
+305,225
| +117% | +$1.44M |
|
3458
ABM Industries
ABM
$2.77B
| $2.84M | ﹤0.01% |
63,091
-546,991
| -90% | -$25.3M |
|
3459
CALL
Johnson Controls International
JCI
$84.6B
| $2.84M | ﹤0.01% |
+41,700
| New | +$3.01M |
|
3460
CALL
Medpace
MEDP
$16.8B
| $2.84M | ﹤0.01% |
+15,000
| New | +$2.74M |
|
|
HHLA.U
3461
DELISTED
HH&L Acquisition Co. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant
HHLA.U
| $2.84M | ﹤0.01% |
285,895
-934,005
| -77% | -$9.34M |
|
|
RCHG
3462
DELISTED
Recharge Acquisition Corp. Class A Common Stock
RCHG
| $2.84M | ﹤0.01% |
286,660
+250,000
| +682% | +$2.46M |
|
3463
Broadridge
BR
$20.9B
| $2.84M | ﹤0.01% |
17,027
+695
| +4% | +$118K |
|
3464
Maximus
MMS
$3.13B
| $2.83M | ﹤0.01% |
34,067
-21,419
| -39% | -$1.83M |
|
3465
Minerals Technologies
MTX
$2.24B
| $2.83M | ﹤0.01% |
40,559
+7,317
| +22% | +$559K |
|
3466
Rhythm Pharmaceuticals
RYTM
$7.38B
| $2.83M | ﹤0.01% |
216,924
+60,108
| +38% | +$918K |
|
|
ORIAU
3467
DELISTED
Orion Biotech Opportunities Corp. Units
ORIAU
| $2.83M | ﹤0.01% |
286,053
-163,647
| -36% | -$1.63M |
|
3468
ProQR Therapeutics
PRQR
$323M
| $2.83M | ﹤0.01% |
337,504
+325,364
| +2,680% | +$2.13M |
|
|
DCH
3469
Dauch Corp
DCH
$1.5B
| $2.82M | ﹤0.01% |
320,064
-389,216
| -55% | -$3.57M |
|
3470
Amcor
AMCR
$21.6B
| $2.82M | ﹤0.01% |
48,610
-258,196
| -84% | -$15.4M |
|
3471
H.B. Fuller
FUL
$3.03B
| $2.82M | ﹤0.01% |
43,635
+18,852
| +76% | +$1.22M |
|
3472
Fulcrum Therapeutics
FULC
$294M
| $2.81M | ﹤0.01% |
99,707
-525,928
| -84% | -$9.97M |
|
3473
Ocular Therapeutix
OCUL
$2.28B
| $2.81M | ﹤0.01% |
281,279
+266,135
| +1,757% | +$2.99M |
|
3474
Advanced Energy
AEIS
$10.9B
| $2.81M | ﹤0.01% |
32,030
+10,349
| +48% | +$968K |
|
3475
PUT
Transocean
RIG
$6.48B
| $2.81M | ﹤0.01% |
741,800
-400
| -0.1% | -$1.46K |
|
Similar funds
Israel Englander's Q3 2021 Portfolio in Review
As of Q3 2021, Israel Englander held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Israel Englander's Q3 2021 filing shows 1,245 new, 2,719 increased, 2,446 reduced and 981 closed positions. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M. The largest sale was Alexion Pharmaceuticals, an estimated $887M.
By sector, the portfolio is most concentrated in Miscellaneous at 58% of assets, up from 55% a quarter earlier, followed by Technology and Financials.
- Israel Englander's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Israel Englander added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Israel Englander's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Israel Englander fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Israel Englander's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Israel Englander opened 1,245 new positions and closed 981 in Q3 2021.
- Israel Englander's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.